div class=ts-pagebutton class=gotoPage data-page=1Page 1button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=1 data-page=1 class=ts-thumb lazyload alt=Page 1: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails1jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=2Page 2button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=2 data-page=2 class=ts-thumb lazyload alt=Page 2: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails2jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=3Page 3button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=3 data-page=3 class=ts-thumb lazyload alt=Page 3: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails3jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=4Page 4button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=4 data-page=4 class=ts-thumb lazyload alt=Page 4: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails4jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=5Page 5button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=5 data-page=5 class=ts-thumb lazyload alt=Page 5: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails5jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=6Page 6button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=6 data-page=6 class=ts-thumb lazyload alt=Page 6: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails6jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=7Page 7button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=7 data-page=7 class=ts-thumb lazyload alt=Page 7: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails7jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=8Page 8button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=8 data-page=8 class=ts-thumb lazyload alt=Page 8: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails8jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=9Page 9button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=9 data-page=9 class=ts-thumb lazyload alt=Page 9: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails9jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=10Page 10button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=10 data-page=10 class=ts-thumb lazyload alt=Page 10: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails10jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=11Page 11button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=11 data-page=11 class=ts-thumb lazyload alt=Page 11: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails11jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=12Page 12button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=12 data-page=12 class=ts-thumb lazyload alt=Page 12: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails12jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=13Page 13button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=13 data-page=13 class=ts-thumb lazyload alt=Page 13: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails13jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=14Page 14button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=14 data-page=14 class=ts-thumb lazyload alt=Page 14: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails14jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=15Page 15button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=15 data-page=15 class=ts-thumb lazyload alt=Page 15: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails15jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=16Page 16button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=16 data-page=16 class=ts-thumb lazyload alt=Page 16: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails16jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=17Page 17button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=17 data-page=17 class=ts-thumb lazyload alt=Page 17: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails17jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=18Page 18button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=18 data-page=18 class=ts-thumb lazyload alt=Page 18: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails18jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=19Page 19button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=19 data-page=19 class=ts-thumb lazyload alt=Page 19: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails19jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=20Page 20button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=20 data-page=20 class=ts-thumb lazyload alt=Page 20: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails20jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=21Page 21button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=21 data-page=21 class=ts-thumb lazyload alt=Page 21: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails21jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=22Page 22button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=22 data-page=22 class=ts-thumb lazyload alt=Page 22: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails22jpg width=140 height=200 divdivdiv class=ts-pagebutton class=gotoPage data-page=23Page 23button div class=ts-imageimg data-url=powerpoint-information-in-this-presentation-is-current-as-of-this-date-r428bgb324htmlpage=23 data-page=23 class=ts-thumb lazyload alt=Page 23: PowerPoint · PDF fileThe information in this presentation is current as of this date R428BGB324 - Oral Axl Inhibitor for Oncology BerGenBio Phase 1 Ongoing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader031vdocumentsusreader031viewer20220304165aa28eff7f8b9a1f6d8d643ahtml5thumbnails23jpg width=140 height=200 divdiv